2027 Biotech Catalyst Calendar

A source-linked calendar of known 2027 biotech catalysts — trial readouts, PDUFAs, filings, and the conferences where data drops.

As of September 24, 2026v4.1 · Sep 24, 2026310 tickers with 2027 eventsMonthly refresh · 1st of each month
Raw JSONSubscribe to confirmed dates (.ics)
1,147events
310tickers
266hard dates
415guidance dates
466inferred dates
52verified PDUFAs · 42 exact dates

Calendar shape

All 1,147 records by disclosed timing bucket. Conference rows are reported separately from drug-catalyst counts.

266 hard415 guidance466 inferred · 40.6%
266 exact hard dates

Month view

Every hard date in the dataset: 201 conferences, 42 PDUFAs, and 23 other dated events.

v4.0 → v4.1

What changed

Notable additions, corrections, and timing updates.

Acceptance-contingent

Watchlist

Live situations that could become 2027 calendar events. They remain outside the dataset until a filing, acceptance, or timing disclosure supports a calendar entry.

Evidence discipline

Methodology

A broad, source-linked sweep of disclosed 2027 binaries, with uncertainty shown rather than buried and known timing gaps kept visible.

HARDExact date from FDA or an event organizer.
GUIDANCECompany-guided window such as Q1 or H2.
INFERREDDerived from registry or submission timelines; highest slip risk.

Universe

The v4.0 dataset contains 1,128 source-linked records across 300 tickers with qualifying clinical or regulatory events. Conference rows are excluded from the ticker-with-events count.

Evidence order

SEC filings → FDA and regulatory records → ClinicalTrials.gov and History of Changes → conference programs → company PRs and decks → genuine wires and verbatim-source fallbacks.

PDUFAs: an event is labeled a PDUFA only when the FDA has accepted the application for review. Filings still awaiting acceptance are not shown as PDUFAs.

What counts

Every clinical data readout regardless of stage; IND, NDA, and BLA filings and acceptances; PDUFAs; posted AdComs; other binary regulatory decisions; and major conferences with stock-relevant data. No date is invented: unguided timelines receive no entry.

Dataset shape

v4.0 contains 1,128 records: 208 Phase 3, 333 Phase 2, 218 Phase 1, 9 preclinical, and 360 regulatory-or-conference records without a clinical phase. Event types include 728 readouts, 43 PDUFAs, 28 NDA filings, 25 BLA filings, 15 INDs, 48 other regulatory events, 2 CHMP opinions, 2 MAA filings, 1 device regulatory decision, 27 HTA decisions, 5 M&A closes, 2 pricing decisions, 1 litigation milestone, 2 key patent expiries, 1 milestone payment, 1 biosimilar launch, 1 biosimilar decision, and 196 conferences.

Date quality is 253 hard, 403 guidance, and 466 inferred. Every row carries a last-checked date.

Impact ratings

Every event carries an impact rating — high, medium, or low — answering one question: how significant could this event be for the company involved? It is an estimate of an event’s binary significance from a published, mechanical formula. It is not a prediction of how the stock will move. A “high” rating does not mean the stock will rise or fall; it means the outcome matters a lot to the company’s value, so the price reaction could be large either way. A “low” rating means the event is unlikely to change the investment picture much, even if the outcome surprises.

The rating starts from the kind of event — approval decisions, Phase 3 readouts, EU opinions, device decisions, and mergers start high; filings, Phase 2 readouts, label expansions, and pricing decisions start medium; early-stage clearances, Phase 1 readouts, and conferences start low — then adjusts for company size. Large companies step down a notch, since one readout rarely moves a giant; small biotechs step up for clinical and regulatory events, since a single readout can be the whole story; mid-sized companies are unadjusted. Company size tiers are rough estimates from public knowledge, and borderline calls were re-checked against a market-cap dataset in v3.0.

This is not investment advice. Impact describes how much an event could matter — not which way it will go, and not whether to buy, sell, or hold.

Known blind spots

  • 40.6% of rows (466/1,147) are inferred. ClinicalTrials.gov primary-completion dates do not equal — or guarantee — public topline disclosure.
  • There are zero hard Phase 3 readout dates in this dataset. Hard dates are organizer-confirmed conferences and FDA-grounded dates, including some PDUFAs; clinical readout timing is guidance or inference.
  • No 2027 AdComs are listed because FDA has not posted them yet.
  • H2 2027 PDUFAs remain incomplete until late-2026 FDA acceptances land. The monthly refresh on the 1st of each month is designed to catch them.
  • Every event carries a source link. Official company PR/IR, SEC filings, FDA, ClinicalTrials.gov, and canonical newswires are used wherever they exist. BioSpace, STAT, Endpoints News, similar established biotech outlets, and call transcripts hosted on Quartr are accepted as legitimate sources. Rows that remain on weaker aggregators, wire mirrors, or trade coverage are kept with confidence explicitly flagged in the evidence note; no row is removed for source quality alone.
  • Unguided programs remain on the watchlist rather than receiving invented dates.

Changelog

v4.0 · Sep 23, 2026
Event drawer with deep links; indication-group filter; catch-up mode; saved filter presets; search operators; personal notes; shareable starred lists; starred iCal/CSV export; glossary, limitations, corrections, developers, and track-record pages; four-step onboarding; iCal subscription feed; offline support; screen-reader pass. Data: 1,126 events across 300 tickers, every row with a last-checked date.

v3.0 · September 23, 2026
New views and tools: 7-day and 30-day calendar views, per-ticker 2027 timelines, starred events with reminders, shareable filtered links, “in N days” countdowns, new-event badges, sort by ticker, a hide-past toggle, trial-registry links on every row, per-event calendar (.ics) downloads, and impact and market-cap filters. Data: 1,127 events across 299 tickers — every event now carries an impact rating (high/medium/low) and a market-cap tier, with related-event links and date-change history on revised rows; one duplicate readout merged and one ticker remapped after an acquisition.

v2.0 · September 23, 2026
3 new catalysts added, 2 PDUFA dates firmed to exact dates, and 24 event dates updated; 2 rows removed.

v1.9 · September 23, 2026
8 new event categories — reimbursement decisions, M&A closings, pricing decisions, litigation milestones, patent expiries, milestone payments, biosimilars; 42 new events.

v1.8 · September 23, 2026
5 new catalysts (Kardigan ×3, Aktis Oncology ×2); timing corrections across the book.

v1.7 · September 23, 2026
48 new catalysts from a company-by-company review (Gilead, BMS, AstraZeneca, Pfizer, Regeneron, Novartis and others); ARIKAYCE added as a PDUFA.

v1.6 · September 21, 2026
28 new events; European regulatory events and device decisions added as categories.

v1.5 · September 20, 2026
60 corrections; obexelimab (ZBIO) and VOXZOGO (BMRN) added as PDUFAs.

v1.4 · September 18, 2026
Corrections applied; 6 new PDUFAs added.

v1.3 · September 18, 2026
Timing corrections; three filings moved to the watchlist pending FDA acceptance.

v1.2 · September 18, 2026
Phase 1 and preclinical coverage completed.

v1.1 · September 18, 2026
Phase 2 readouts added.

v1.0 · September 18, 2026
Phase 3, regulatory, and conference foundation compiled.